Cavers Greg purchased $39K of HELP (indirect holdings)

Cavers Greg (Chief Financial Officer) purchased 3,000 indirectly-held shares of Helus Pharma Inc. (HELP) at $12.91 on 2026-09-29.

Original reporting
SEC EDGAR · Cavers Greg
Published Oct 2, 2026, 12:13 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 12:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$HELP
Bullish
medium confidence
Mentioned
$HELP
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HELPBullishLow
01

Why it matters

The CFO's modest purchase provides a slight positive cue but is unlikely to drive significant price movement.

02

Market read

Small insider buy; limited trading relevance.

03

What to watch

The transaction size is tiny relative to market cap and may not move the stock.

Relevance 4/10Novelty 3/10Timing: after-hours filing

Background

Form 4 filing discloses insider transactions; such filings are primary sources of corporate insider activity.

Company-level read

Ticker impact

$HELPBullishMedium confidence
Context

CFO Greg Cavers bought 3,000 HELP shares at $12.91 each, a $38,730 purchase disclosed on Form 4.

Expected impact

likely modest upward pressure as market prices in insider buying

Evidence & confidence

The purchase is small relative to market cap, but CFO buying is a positive signal; impact is limited.

Market effects

Minimal effect on biotech sector; typical insider trades are routine.

No regional impact beyond the company's share price.

Negligible global relevance.

Counterpoint

The purchase may be a routine portfolio rebalancing, not a strong confidence signal.

Key entities

  • Helus Pharma Inc.

    Biopharmaceutical company issuing the Form 4.

  • Greg Cavers

    Chief Financial Officer of Helus Pharma.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$HELPMed

HELP Stock Slides As Suicide Attempt Overshadows Strong Late-stage Depression Trial Data

HELP stock declined despite positive late-stage trial data for its depression drug, HLP003. The drug showed significant improvements in patients, with 56% seeing at least a 50% improvement at six weeks. Analysts like Lucid Capital raised their price target to $79, citing strong results, while Jefferies and Barclays maintained 'Buy' and 'Overweight' ratings, respectively. Retail sentiment on Stocktwits turned 'extremely bullish'.

$HELPMedAI 8/10

Helus Pharma falls 10.5% despite positive HLP003 trial

Helus Pharma (HELP) reported positive results for its experimental drug HLP003, meeting the primary endpoint in a late-stage depression trial. Despite this, shares fell 10.5% to $7.94, with three serious adverse events disclosed. Analysts noted strong efficacy and no fundamental reason for the decline. The company is also developing HLP004 for anxiety and expects to identify an HLP005 candidate in late 2027.

MedAI 8/10

Serious adverse events mar robust efficacy data for Helus’ psychedelic in major depression

Helus Pharma reported that its deuterated psilocin therapy, HLP003, significantly reduced major depressive disorder symptoms in a late-stage trial, but its stock fell due to three undisclosed serious adverse events. The trial met primary and secondary endpoints, with a 19.5-point reduction in symptoms versus 11.9 for placebo. Analysts noted the efficacy but emphasized the need for safety clarification. The company expects further trial results in 2027.

HighAI 8/10

Helus Pharma's psychedelic depression drug succeeds in late-stage study, shares jump

Helus Pharma reported that its psychedelic drug, HLP003, showed significant improvement in depression symptoms in a late-stage trial. The drug, a modified version of psilocin, is designed to be used with standard antidepressants. The company's shares rose over 20% in premarket trading. According to Helus, 56.3% of patients treated with HLP003 saw their symptoms cut by at least half, compared with 28.2% on placebo.